NANOTAG BIOTECHNOLOGIES GMBH

NANOTAG BIOTECHNOLOGIES GMBH operates in the scientific research and development domain, with primary expertise centered on advanced biotechnological innovation and molecular diagnostics. Based on its NAICS classification of 541714, the company focuses on research and development in biotechnology, likely engaging in the design and development of novel biosensors, molecular tagging systems, or diagnostic platforms leveraging nanoscale technologies. Their technical capabilities appear to include molecular labeling, bioconjugation chemistry, and the integration of nanomaterials for targeted biological detection—specializations that support applications in life sciences, medical research, and environmental monitoring. The firm’s differentiation lies in its precision engineering of nanoscale biological interfaces, enabling high-sensitivity, low-background detection systems critical for next-generation diagnostic tools. No award history is available to confirm specific agency engagements, so no definitive patterns of federal client relationships can be inferred. Similarly, without contract data, it is not possible to identify vertical specializations or dominant market sectors beyond the broad scope of biotechnological R&D. The company is structured as a 2L entity, indicating a small business classification under federal contracting rules, and is headquartered in Göttingen, Germany. While it maintains a presence in the European research ecosystem, no U.S. government certifications or accreditations are listed, and there is no evidence of formal participation in U.S. federal procurement programs. Its market positioning is that of a specialized R&D provider in biotechnology, likely serving academic, pharmaceutical, or government research institutions through technical collaboration or contract research arrangements, though direct federal contracting activity cannot be confirmed from available data.